Eyepoint Pharmaceuticals announced that its experimental treatment for wet age-related macular degeneration failed to meet primary goals in a Phase 3 trial, likely delaying regulatory approval and causing stock prices to drop. This setback highlights the high risk and volatility inherent in clinical drug development for eye diseases, impacting both investors and patients awaiting new treatments. Meanwhile, Novartis decided not to pursue reimbursement for its rare kidney disease treatment in Canada due to challenging access regulations, underscoring the complex market entry challenges for innovative pharmaceuticals.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
